Navigation Links
New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy
Date:9/24/2008

PORTO, Portugal, September 24 /PRNewswire/ --

- Novel Treatment Also Demonstrated Significant Improvement in Quality of Life and Reduction in Depressive Symptoms

Positive data from three phase III studies presented today at the 8th European Congress of Epileptology, Berlin, Germany, demonstrated that Zebinix(TM) (1) (eslicarbazepine acetate), a novel once daily anti-epileptic agent, significantly reduced the frequency of partial seizures in patients with refractory partial epilepsy, in combination with other anti-epileptic agents.(2,3,4)

Zebinix(TM) is one of the proposed EU trade names for eslicarbazepine acetate.

In addition, treatment with Zebinix(TM) also significantly improved patient quality of life, reduced depressive symptoms and demonstrated sustained reduction in partial seizure frequency during a one-year open label period.(5,6,7)

"When assessing the potential of anti-epileptic agents it is as important to consider the implications on the quality of a patient's day-to-day life, as well as effective seizure control," said Professor E. Ben-Menachem, University of Goteborg, Sweden. "In addition to sustained reductions in seizure frequency, Zebinix(TM) also demonstrated a significant improvement in patient quality of life and reduction in depressive symptoms."

Professor Christian Elger, Director and Head of the Department of Epileptology at the University of Bonn, Germany, added "these data suggest that Zebinix(TM) may become an important treatment option for patients whose seizures are not adequately controlled with existing anti-epileptic agents."

Epilepsy is one of the most common neurological diseases affecting almost one in 100 people.(8) Treatment of partial seizures, the most common type of epilepsy, presents a constant challenge with over half of patients not achieving adequate seizure control with current anti-epileptic drugs.(9)

Zebinix(TM), a new anti-epileptic drug that selectively inhibits the rapid firing nerve cells that cause seizures, has been developed to address the need for a new anti-epileptic agent that offers a reduction in seizure frequency combined with a favourable tolerability profile. Zebinix(TM) is currently under review by the EMEA (European Medicines Agency) for the treatment of partial-onset seizures with or without secondary generalisation in combination with other anti-epileptic drugs. A US NDA (New Drug Application) is expected later in 2008 or early 2009.

About the trials

The three phase III, multi-centre, randomised, placebo controlled trials involved more than 1,000 patients from 23 countries. Patients had a history of at least four partial seizures per month despite treatment with up to three concomitant anti-epileptic drugs.(2,3,4)

During the trials, patients were randomised to eslicarbazepine acetate or placebo and after a 2-week titration period, were assessed over a 12 week maintenance period, with continued follow-up over a one year open-label period.(2,3,4,7)

Efficacy

Over the 12 week maintenance period, Zebinix(TM) 800mg and 1200mg reduced seizure frequency by over one third, and was significantly more effective than placebo. This significant decrease in seizure frequency was sustained over the one-year open label treatment period and was consistent regardless of baseline therapy..(2,3,4) Similar positive findings were observed in the responder rate (greater-than-or-equal-to 50% decrease in seizure frequency) for Zebinix(TM) 800mg and 1200mg that ranged between 32% and 43% across all three phase III trials. (2,3,4)

Tolerability

The safety profile of Zebinix(TM) was favourable. The majority of treatment related adverse events were mild or moderate in severity and after 6 weeks, no relevant differences in the incidence of adverse events were apparent between patients treated with eslicarbazepine acetate and patients treated with placebo. In patients treated with Zebinix(TM) the incidence of CNS side effects was low. (2,3,4)

Quality of life and depressive symptoms

The effect of Zebinix(TM) on quality of life was analysed using the Quality of Life Epilepsy Inventory-31 (QOLIE-31) scale. There was a statistically and clinically significant improvement from baseline during long-term open-label therapy, including:5

- 16 per cent mean relative improvement in overall quality of life

(p<0.0001).

- 51 per cent improvement in worry about seizures (p<0.0001)

- 41 per cent improvement in social function (p<0.001)

Improvement in depressive symptoms was also measured using the Montgomery Asberg Depression Rating Scale (MADRS). Zebinix(TM) demonstrated a significant improvement in depressive mood and symptoms from baseline (p<0.0001).(6)

Notes to Editors

About partial seizures and their treatment

Epilepsy is one of the most common neurological diseases, affecting almost 1 in 100 people.(8) Treatment of partial seizures, the most common type of epilepsy, presents a constant challenge - up to 58% of patients with partial seizures do not achieve seizure control with current antiepileptic drugs.(9)

Furthermore, adverse events, such as dizziness and somnolence, are highly prevalent with existing anti-epileptic agents and may affect as many as 97% of patients.(10) Hence, there is a need for new anti-epileptic agents that offer effective reduction in seizure frequency combined with a favourable safety profile.

Epilepsy is characterised by abnormal firing of impulses from nerve cells in the brain. In partial-onset epilepsy, these bursts of electrical activity are initially focused in specific areas of the brain, but may become more generalised; the symptoms vary according to the affected areas. Nerve impulses are triggered via voltage-gated sodium channels in the nerve cell membrane.

About Zebinix(TM)

Zebinix(TM) is a novel voltage-gated sodium channel blocker that has been designed to reduce the frequency of partial-onset seizures when used in combination with other anti-epileptic drugs.

This treatment has the potential to offer a new therapeutic option for patients who continue to suffer partial seizures despite receiving other anti-epileptic agents, with the potential for additional benefits in terms of improvements in quality of life and depressive symptoms.(2,3,4,5,6,7)

About BIAL

Founded in 1924, BIAL is an international pharmaceuticals group with products available in nearly 30 countries over four continents. BIAL group is the largest Portuguese pharmaceutical company and is based in S. Mamede do Coronado, Portugal.

BIAL is strongly committed to therapeutic innovation on research and development every year. This commitment has been recognised in the group's recent integration into the EFPIA (European Federation of Pharmaceutical Industries and Associations), which is dedicated to encouraging research and the development of new therapeutic options.

Key research areas for BIAL are the central nervous system, the cardiovascular system and allergology. BIAL's dedication to research is further demonstrated by the research grants and awards offered by the BIAL Foundation.

Further information about BIAL can be found at http://www.bial.com

References

(1). Zebinix(TM) is one of the proposed EU trade names for Eslicarbazepine acetate

(2). Elger C, Halasz P, Maia J et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-301 Study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(3). Hufnagel A, Ben-Menachem E, Gabbai A et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 Study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(4). Lopes-Lima J, Gil-Nagel A, Maia J et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 Study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(5). Cramer J, Maia J, Almeida L, Soares-da-Silva P. Quality-of-life improvement during long-term treatment with eslicarbazepine acetate. Abstract and poster, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(6). Hodoba D, Członkowska A, Cramer J. Depressive symptoms improvement during long-term treatment with eslicarbazepine acetate. Abstract and poster, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(7). Guekht A, Elger C, Halasz P et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate: results of a 1-year open-label extension study. Abstract and oral communication, presented at the 8th European Congress on Epileptology, Berlin, Germany, 21-25 September 2008.

(8). WHO Atlas: Epilepsy Care in the World. WHO 2005

(9). Brodie MJ. Management strategies for refractory localization-related seizures. Epilepsia 2001;42(Suppl 3):27-30

(10). Mei PA, Montenegro MA, Guerreiro MM, Guerreiro CA. Pharmacovigilance in epileptic patients using antiepileptic drugs. Arq Neuropsiquiatr 2006 Jun;64(2A): 198-201. Epub 2006 Jun 9

For more information please contact:

BIAL (head office)

Francisco Osorio

Tel.: +351-22-986-6100

Mobile: +351-96-346-9968

francisco.osorio@bial.com

Paul Gittins

Red Health

Tel.: +44-207-025-6571

Mobile: +44-7958-533-462

paul.gittins@redconsultancy.com


'/>"/>
SOURCE BIAL
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
2. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
3. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
4. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
7. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
11. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
Breaking Medicine Technology:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):